Loading
A phase 1/2 trial of VLS-1488 in non-small-cell lung cancer, triple-negative breast cancer, head and neck squamous cell carcinoma, ovarian cancer, sarcomas and endometrial cancer, run by Volastra Therapeutics, Inc., now recruiting.
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer is a phase 1/2 interventional study registered as NCT05902988 by Volastra Therapeutics, Inc., with 200 participants planned, started 2023-10-18 and due to reach its primary completion in 2026-06. Interventions recorded: VLS-1488.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/